Recent studies have centered on the intersection of glucagon-like peptide-1|GIP|GCGR activator therapies and DA signaling. While GCGR agonists are widely employed for treating type 2 diabetes, their unexpected effects on reward circuits, specifically mediated by dopaminergic systems, are receiving considerable interest. This report presents a summa